» PHI links up with two regenerative medicine networks
» SynAct Pharma's CEO comments on study data from EXPAND
» Toleranzia's CEO: "Several large companies are following us"
» WntResearch provides update ahead of TO6 release
» Dicot doses first phase I participants
Read BioStock's weekly newsletter for v.35 here.
See the BioStock Investor Pitch with Toleranzia and CEO Charlotte Fribert via the banner below.
Morning news
BioInvent announces that research milestones have been achieved in the collaboration with Exelixis which provides a milestone payment of USD 1 million. Read more.
Implantica receives MDR certification for RefluxStop. Read more.
Subscription period in Arcede Pharma The rights issue ends tomorrow, September 8th. Read more.
Medivir presents data on the additive effect of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA. Read more.
sectra announces that Israel's largest healthcare provider selects the company's digital pathology solution for cancer diagnostics. Read more.
ExpreS2ion Biotechnologies announces that the exercise period for warrants of series TO 8 begins today. Read more.
Contigo Care has today appointed Ulrika Giers to new CEO as of October 1, 2023. Read more.
Tomorrow, Friday, is the last day to sign up. Redwood Pharma Rights issue of units for an initial maximum of approximately SEK 31,6 million. Read more.
Jonas Jarvius plans to step down as CEO Q-Line before the summer of 2024 to take over as CEO of a US-based life science company. Read more.
Today marks the start of the usage period for Tendonitis warrants of series TO 2. Read more.
QuiaPEG Pharmaceuticals informs that tomorrow is the last day for exercising warrants of series TO10. Read more.
On the occasion of the extraordinary general meeting to be held on September 27, Circio in for a webcast with Q&A on September 19th. Read more.
Reports
Communiqués
News since Wednesday lunch
Stayble Therapeutics announces the last patient's last visit in the Phase IIb clinical study. Read more.
Cyxone followed up on its communication about the new strategy and upcoming activities. Read more.
Amniotic procured top guarantee commitments and entered into additional subscription commitments for a fully secured rights issue. Read more.
Analyst Group published an analysis of Aptahem entitled "Waiting for resumed study". Read more.
Study confirms the benefits of Modulights technology and photoimmunotherapy for ovarian cancer. Read more.
New publication from National University of Singapore who use Attanas technique for studying the immune response of healthy individuals exposed to tuberculosis. Read more.
Bioretec received R&D grants from Business Finland for the development of surface treatments for next-generation biodegradable implants. Read more.
Ray Intelligence has entered into an agreement with Formue Nord Marknadsneutral and intends to decide on a directed new issue of shares. Read more.
Ortivus was awarded a contract for the delivery of MobiMed to Region Jämtland Härjedalen. Read more.
Pharmiva completes clinical study of Vernivia. Read more.
American biotechnology company extended lease of PExA instruments. Read more.
AddLife invited to Capital Markets Day on September 15. Read more.
Nanexa presents at ISPOR Europe 2023. Read more.
IO Biotech announced participation in upcoming investor conferences. Read more.
This morning's price development
Winner: PharmaLundensis + 30%, Gabather +15,12%, Arcede Pharma +11,73%, RLS Global +11,69%, Cereno Scientific +10,43%
Förlorare: Biovica International -7,31%, Amniotics -6,76%, Scandion Oncology -6,37%, Abliva -6,32%, SynAct Pharma -5,56%
Index: OMSX30 2197 -0,25%, Healthcare -0,15%
More from BioStock
» Annexin CEO: “By far our biggest success in a long time”
» Toleranzia's CEO on development and issuance
» Aptahem's CEO comments on Q2 and looks ahead
» BrainCool comments on the increased order intake
» Stayble includes first patient in herniated disc study